| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 05/19/2005 | WO2004041924A3 Non-phosphorous-linked oligomeric compounds and their use in gene modulation |
| 05/19/2005 | WO2004037811A8 Selected cgrp antagonists, method for production and use thereof as medicament |
| 05/19/2005 | WO2004028540A9 Anti-neurodegenerative agents |
| 05/19/2005 | WO2004024868A3 Product and process for liquefaction of mucus or sputum |
| 05/19/2005 | WO2004016764A3 eNOS MUTANTS USEFUL FOR GENE THERAPY |
| 05/19/2005 | WO2003093290A8 Nucleoside derivatives for treating hepatitis c virus infection |
| 05/19/2005 | WO2003092592A3 Dengue tetravalent vaccine containing a common 30 nucleotide deletion in the 3'-utr of dengue types 1,2,3, and 4, or antigenic chimeric dengue viruses 1,2,3, and 4 |
| 05/19/2005 | WO2003049678A3 Mitotic kinesin inhibitors |
| 05/19/2005 | WO2002069893A3 Treatment of neurological disease |
| 05/19/2005 | US20050108784 Expression vector comprising nucleotide sequences coding spinocerebellar ataxia-1 gene for use in treatment and prevention of nervous system disorders |
| 05/19/2005 | US20050107621 Catalytic reduction with ruthenium/diphenylethylenediamine derivative; amidation, deesterification |
| 05/19/2005 | US20050107616 Alpha-ketoamide derivatives as cathepsin k inhibitors |
| 05/19/2005 | US20050107611 For use as adenosine receptor ligands; immunostimulants; contraceptives |
| 05/19/2005 | US20050107607 Processes for preparing novel methylene blue derivative |
| 05/19/2005 | US20050107606 Process for producing optically active sulfoxide derivative |
| 05/19/2005 | US20050107581 Steam stripping beads under vacuum; divinyl benzene/ethyl vinyl benzene copolymers; dilution; for production of cephalosporin C and insulin |
| 05/19/2005 | US20050107476 Alkoxy-substituted indanes and the production thereof |
| 05/19/2005 | US20050107475 Methods of using farnesoid x receptor (frx) agonists |
| 05/19/2005 | US20050107474 Pharmaceutical compositions for the treatment of infections of the respiratory system by pathogenic agents |
| 05/19/2005 | US20050107472 administering vitamin k derivatives for prophylaxis of neurodegenerative diseases associated with protein aggregation or neurofibrillary tangles |
| 05/19/2005 | US20050107470 treatment of infertility |
| 05/19/2005 | US20050107468 reacting thioacids with 2-aralkyl acrylic acids in the presence of Lewis acids containing transition metals to from 3-thioacyl-2-aralkylpropionic acids |
| 05/19/2005 | US20050107466 administering selective serotonin reuptake inhibitors as antidepressants and anxiolytic agents |
| 05/19/2005 | US20050107465 Composition for treating inflammatory bowel disease |
| 05/19/2005 | US20050107464 Antitumor agent containing lactic acid oligomer mixture |
| 05/19/2005 | US20050107463 Novel prostamides for the treatment of glaucoma and related diseases |
| 05/19/2005 | US20050107461 Drug combination therapy |
| 05/19/2005 | US20050107460 N-heteroaryl-, naphthyl or azulenyl-substituted 1-azabicycloalkylcarboxamides; treatment and/or prophylaxis of impairments of perception, concentration, learning and/or memory |
| 05/19/2005 | US20050107458 used as diagnostic kits, bioassay and/or drugs for preventing cancers, Alzheimer's disease, amyotrophic lateral sclerosis, Parkinson's disease, stroke, ischaemia, Huntington's disease, epilepsy, multiple sclerosis, neuropathy, or injuries of the brain or spinal chord, or as tyrosine kinase inhibitors |
| 05/19/2005 | US20050107457 Indazole derivatives as JNK inhibitors and compositions and methods related thereto |
| 05/19/2005 | US20050107455 Novel tricycloimidazoline derivatives method for production and use thereof as medicaments |
| 05/19/2005 | US20050107454 crystallization of 1-(4-chlorophenoxy)-1-(1H-imidazolyl)-3,3-dimethyl-2-butanone in solvents, then washin and desolventizing; cosmetics: shampoos; fungicides |
| 05/19/2005 | US20050107453 Resolution of 3-amino alkylnitriles |
| 05/19/2005 | US20050107452 Black soybean polysaccharides |
| 05/19/2005 | US20050107451 prevention of neuronal cell apoptosis by administering (Tetrazol-5-yl)glycine, neriifolin or cevadine, as neuroprotective agents |
| 05/19/2005 | US20050107450 administering Peroxisome Proliferator Activated Receptors (PPAR-gamma) activators according to a dosage schedule which comprises a cycle of less than daily administration |
| 05/19/2005 | US20050107449 Substituted thiazoles and oxazoles, e.g., 4-{1-[4-[2-(2-Chloro-6-fluoro-phenyl)-ethyl]-2-(4-trifluoromethyl-phenyl)-thiazol-5-yl]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid; treating atherosclerosis and diabetes and creating Syndrome X |
| 05/19/2005 | US20050107446 Two components mixture comprising a powder of atorvastatin with an alkalizing agent that forms a pH greater than 5 and a second component without the alkalizing agent; treating angina pectoris, hypertension, atherosclerosis |
| 05/19/2005 | US20050107445 Active compounds with carbamic acid for diseases such as cancer, leukemia, atheriosclerosis, alzheimers disease or arthritis |
| 05/19/2005 | US20050107442 Compounds that modulate PPAR activity and methods of preparation |
| 05/19/2005 | US20050107440 Rosiglitazone edisylates and their use as antidiabetics |
| 05/19/2005 | US20050107439 Composition and method for treating emesis |
| 05/19/2005 | US20050107438 mixtures of dabigatran etexilate and lipophilic liquid, solid, or semi-solid carriers |
| 05/19/2005 | US20050107436 Compounds for inflammation and immune-related uses |
| 05/19/2005 | US20050107435 antibiotics such as (5S,5S')-N-(3-{4'-[5-(Acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2,2'-difluoro-biphenyl-4-yl}-2-oxo-oxazolidin-5-ylmethyl)-acetamide, used for treating a bacterial infections in mammals |
| 05/19/2005 | US20050107434 heterocyclic amines such as 1-Cyclopentyl-4-{2-[5-(4-methanesulfonylphenyl)[1,2,4]oxadiazol-3-yl]ethyl}piperidine and salts, used as histamine-H3 receptor antagonists for treatment of nervous system, cardiovascular , respiratory system, gastrointestinal system and endocrinological system disorders |
| 05/19/2005 | US20050107432 such as 1-benzyl-4-[(5,6-dimethoxy-1-indanon)-2-ylidene]methylpiperidine, used for treating nervous system, neurodegenerative and/or psychological disorders |
| 05/19/2005 | US20050107431 Piperidinylchromen-6-ylsulfonamide compounds as 5-hydroxytryptamine-6 ligands |
| 05/19/2005 | US20050107430 inhibiting infections by microorganism or viruses by administering dibenzo[a,g]-fluorenyl and chrysenyl compounds |
| 05/19/2005 | US20050107429 Aqueous liquid preparations and light-stabilized aqueous liquid preparations |
| 05/19/2005 | US20050107428 Antiinflammatory agents; autoimmune diseases; rheumatic diseases; anticholesterol agents; cardiovascular disorders |
| 05/19/2005 | US20050107425 in mammals comprising administering alpha-7-nicotinic acetylcholine receptors (alpha-7-nAChR) agonists, and psychostimulants and/or monoamine reuptake inhibitors |
| 05/19/2005 | US20050107423 Quinolone antibiotics such as 1-Cyclopropyl-6-fluoro-7-(4-hydroxy-hexahydro-cyclopenta[c]pyrrol-2-yl)-8-methyl-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid, used for treating gramnegative or grampositive bacterial infection in mammals |
| 05/19/2005 | US20050107422 Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity |
| 05/19/2005 | US20050107421 Nitrogen compounds such as 2-Butyl-1-(2-methylpropyl)-1H-tetrazolo[1,5-a]imidazo[4,5-c][1,8]naphthyridine, used to induce biosynthesis of cytokines such as interferons and tumor necrosis factors, or for prophylaxis of viral diseases |
| 05/19/2005 | US20050107420 mixtures of phosphodiesterase inhibitors and anticholinergic agents, used for treating respiratory system disorders such as asthma or chronic obstructive pulmonary disease |
| 05/19/2005 | US20050107419 E.g., Ethyl 2-[2-(4-fluorophenyl)ethyl]-4-(4-{[(2-furylmethyl)amino]carbonyl}phenyl)-5-oxo-8,9-dihydro-5H,7H-pyrazolo[1',2':1,2]pyrazolo[3,4-b]pyridine-3-carboxylate; analogous compounds based on the 7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizine ring; osteoporous; bone disorders; osteoarthritis |
| 05/19/2005 | US20050107418 Macrolides |
| 05/19/2005 | US20050107417 Medicaments for inhalation comprising a novel anticholinergic and a betamimetic |
| 05/19/2005 | US20050107416 17-hydroxy 4-aza androstan -3-ones as androgen receptor modulators |
| 05/19/2005 | US20050107415 Opioid and opioid-like compounds and uses thereof |
| 05/19/2005 | US20050107413 pyrimidine derivatives such as 4-Chloro-5,6-diphenyl-2-(trifluoromethyl)pyrimidine, used for the treatment of inflammation and immunological diseases |
| 05/19/2005 | US20050107411 Method for treating circadian rhythm disruptions |
| 05/19/2005 | US20050107410 Compound possessing affinity at 5ht1-type receptors and use thereof in therapy of cns disorders |
| 05/19/2005 | US20050107407 Method for treating athlete's foot |
| 05/19/2005 | US20050107406 Angiogenesis inhibitors |
| 05/19/2005 | US20050107405 administering cyclic guanosine monophosphate phosphodiestarase (cGMP PDE5) inhibitors such as sildenafil salts, as analgesics or antispasmodic agents |
| 05/19/2005 | US20050107404 Mitotic kinesin inhibitors |
| 05/19/2005 | US20050107403 Carbonylpyridine or carbonylpyrimindine compounds containing another nitrogen containing ring; useful in the treatment of inflammatory, metabolic or malignant conditions |
| 05/19/2005 | US20050107402 4-Oxo-1-(3-substituted phenyl-1,4-dihydro-1,8-naphthyridine-3-carboxamide phosphodiesterase-4 inhibitors |
| 05/19/2005 | US20050107400 4-[2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-[2-(1H-imidazol-5-yl)ethyl]-2-pyridinamine, used for the prophylaxis or treatment of herpes viral infections in humans |
| 05/19/2005 | US20050107399 Cytokine inhibitors |
| 05/19/2005 | US20050107398 benzamide compounds labeled with detectable radionuclides that selectively bind to cancer cells, used for medical diagnosis such as tomography |
| 05/19/2005 | US20050107397 Sulfonamide derivatives as d3-receptor agonists |
| 05/19/2005 | US20050107396 for the treatment of psychotic disorders and Parkinson's disease; crystalline polymorph |
| 05/19/2005 | US20050107395 1-Methyl-cyclohexanecarboxylic acid {2-[4-(2-methoxy-phenyl)-piperazin-1-yl]-1-pyridin-3-ylmethyl-ethyl}-amide; used for treating a condition modulated by serotonin 5-HT1A receptors in the central nervous system and in the body of mammals |
| 05/19/2005 | US20050107394 Novel use of selective pde5 inhibitors |
| 05/19/2005 | US20050107393 4-(diarylmethyl)-1-piperazinyl derivatives |
| 05/19/2005 | US20050107392 treatment of disease such as diabetes, obesity, hyperlipidemia, and atherosclerotic disease; e.g. ethyl (5-methoxy-2,3-dihydro-1H-inden-1-ylidene)ethanoate |
| 05/19/2005 | US20050107390 i.e. 7-[(3R)-3-Amino-4-(3,4-difluorophenyl)butanoyl]-3-methyl-6-(phenylmethyl)-5,6,7,8-tetrahydro-1,2,4-triazolo[4,3-a]pyrazine, dihydrochloride; antilipemic, antiobesity |
| 05/19/2005 | US20050107389 Novel heterocyclic amide derivatives and their use as dopamine D3 receptor ligands |
| 05/19/2005 | US20050107388 Heteroaromatic urea derivatives as vr-1receptor modulators for treating pain |
| 05/19/2005 | US20050107387 Compositions of a cyclooxygenase-2 selective inhibitor and a peroxisome proliferator activated receptor agonist for the treatment of ischemic mediated central nervous system disorders |
| 05/19/2005 | US20050107386 Methods of treating diseases and disorders by targeting multiple kinases |
| 05/19/2005 | US20050107385 Aromatic prodrugs of propofol, compositions and uses thereof |
| 05/19/2005 | US20050107384 to inhibit proliferative conditions, such as cancer and psoriasis; detecting or identifying a HDAC in a biological sample comprising detecting or measuring the formation of a complex between a labelled compound as defined in claim (I) and a HDAC |
| 05/19/2005 | US20050107383 such as 2-(2-propenylthio)-4-(4-trifluoromethylphenyl)benzonitrile; for farm and garden pests including mites, lepidopterans, hemipterans, hymenopterans, orthopterans and isopterans; antiviral agent, fungicide, herbicide |
| 05/19/2005 | US20050107381 e.g. 2-[2-(3,5-Difluoro-phenyl)-acetylamino]-N-pyridin-2-yl-butyramide; inhibiting A beta -production; Alzheimer's disease, hereditary cerebral hemorrhage with amyloidosis, cerebral amyloid angiopathy, a prion-mediated disease, inclusion body myositis, stroke, multiple sclerosis and Down's Syndrome |
| 05/19/2005 | US20050107380 Administering substance P receptor antagonist selected from the group consisting of L 742694, L 758298, and LY 303241, a non-toxic magnesium compound and a pharmaceutically acceptable vehicle |
| 05/19/2005 | US20050107379 antithrombolytic agents such as (E)-2-(5-Chlorothien-2-yl)-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}ethenesulfonamide, used for therapy of cardiovascular disorders |
| 05/19/2005 | US20050107377 3-(Aminoalkoxyphenyl)-substituted, e.g., 1-(4-benzo[b]thiophen-3-yl-phenoxy)-3-benzylamino-propan-2-ol; treatment of conditions such as Attention Deficit Hyperactivity Disorder, Obsessive-Compulsive Disorder, Psychoses, Substance Abuse, Parkinson's Disease, Tourette Syndrome and Tardive Diskinesia |
| 05/19/2005 | US20050107374 Hydroxybenzimidazole pyrimidines or pyridines, as for example 4-(2-((2,6-dimethylphenyl)oxy)-1H-benzimidazol-1-yl)-N-(4-(4-methyl-1-piperazinyl)phenyl)-2-pyrimidinamine; for treatment of protein tyrosine kinase-associated disorders such as immunologic disorders |
| 05/19/2005 | US20050107372 2-(Quinolonyl)-fused heterocycles as androgen receptor modulators |
| 05/19/2005 | US20050107371 reduction of glucose, insulin, free fatty acids; treatment, control and prevention of diabetes, obesity, atherosclerosis, vascular inflammation and their related diseases; e.g. 7-[2-(5-Methyl-2-phenyl-4-oxazolyl)ethoxy]chromane-3-carboxylic Acid |
| 05/19/2005 | US20050107369 Heteroaromatic selective inhibitors of neuronal nitric oxide synthase |
| 05/19/2005 | US20050107368 Inhibitors of cathepsin S |
| 05/19/2005 | US20050107367 2-(morpholin-4-yl)-6-phenyl-thiopyran-4-one; treating diseases which are retroviral mediated or ameliorated by the inhibition of DNA-PK |
| 05/19/2005 | US20050107366 Spin trapping pharmaceutical compositions and methods for use thereof |
| 05/19/2005 | US20050107365 adrenoceptor or G-protein coupled receptors inhibitors such as 3-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-6,7-dimethoxy-2H-benzo[1,2,4]-thiadiazine-1,1-dioxide and carriers, used for prophylaxis of urogenital disorders, or as analgesics |
| 05/19/2005 | US20050107364 Viricides for infections caused by an RNA-containing virus; enzyme inhibitors for a hepatitis C virus (HCV) polymerase; inhibiting HCV viral replication; liver cirrhosis; e. g., 3-(1,1-dioxido-4H-1,2,4-benzothiadiazin-3-yl)-4-hydroxy-1,1-dipropyl-2(1H)-naphthalenone |